Gapping down
In reaction to earnings/guidance:
- VIPS -12.7%, ATGE -10.5%, JKHY -6%, CREE -4.6%, ALC -4.6%, A -2.9%
Other news:
- SRNE -10.7% (terminates CFO immediately)
- SABR -8.7% (stock offering)
- ALBO -7.4% (clinical trial results did not achieve proof-of-concept for other key NASH measures)
- PLYM -6.6% (upsizes and prices offering of 7,500,000 shares of its common stock at $12.85 per share)
- KMDA -5.4% (Kamada and Kedrion Biopharma announce results from a U.S. post-marketing pediatric trial of KEDRAB)
- GILD -4.7% (receives Complete Response Letter from FDA for Filgotinib)
- BIIB -1.3% (FDA approves Mylan's generic version of BIIB's Tecfidera)
Analyst comments:
- CREE -4.6% (downgraded to Mkt Perform from Mkt Outperform at JMP Securities)
- KSS -1.5% (downgraded to Underperform from Hold at Gordon Haskett)
- ETRN -1.4% (downgraded to Underperform from Neutral at BofA Securities)
- PPL -0.5% (downgraded to Neutral from Buy at Mizuho)